Heritage Investors Management Corp Buys 1,378 Shares of Zoetis Inc. $ZTS

Heritage Investors Management Corp raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 196,467 shares of the company’s stock after acquiring an additional 1,378 shares during the quarter. Zoetis comprises approximately 1.0% of Heritage Investors Management Corp’s holdings, making the stock its 28th biggest position. Heritage Investors Management Corp’s holdings in Zoetis were worth $30,639,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Amalgamated Bank lifted its holdings in Zoetis by 2.1% during the second quarter. Amalgamated Bank now owns 96,278 shares of the company’s stock valued at $15,015,000 after purchasing an additional 1,948 shares during the last quarter. Atria Investments Inc lifted its holdings in shares of Zoetis by 8.4% in the second quarter. Atria Investments Inc now owns 100,840 shares of the company’s stock worth $15,726,000 after buying an additional 7,856 shares in the last quarter. Spinnaker Trust lifted its holdings in shares of Zoetis by 37.1% in the second quarter. Spinnaker Trust now owns 1,823 shares of the company’s stock worth $284,000 after buying an additional 493 shares in the last quarter. Savvy Advisors Inc. lifted its holdings in shares of Zoetis by 54.0% in the second quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after buying an additional 1,114 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of Zoetis by 12.2% in the second quarter. Assetmark Inc. now owns 26,409 shares of the company’s stock worth $4,119,000 after buying an additional 2,876 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 1.0%

ZTS stock opened at $143.97 on Thursday. The company has a market capitalization of $63.80 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 2.34 and a beta of 0.90. Zoetis Inc. has a one year low of $139.34 and a one year high of $183.81. The company’s 50 day moving average price is $147.63 and its two-hundred day moving average price is $153.48. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue was up 4.2% compared to the same quarter last year. During the same period last year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Analyst Ratings Changes

ZTS has been the topic of a number of recent analyst reports. Argus reissued a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $195.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.